Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

22 Jul 2010 13:30

RNS Number : 7758P
PuriCore Plc
22 July 2010
 



 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Puricore plc

 

2 Reason for the notification (please tick the appropriate box or boxes):

 

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

Share Capital Consolidation

X

 

3. Full name of person(s) subject to the notification obligation:

 

Perpetual Income & Growth Trust Ltd

 

4. Full name of shareholder(s) (if different from 3.):

 

5. Date of the transaction and date on which the threshold is crossed or reached:

 

02 July 2010

6. Date on which issuer notified:

 

05 July 2010

7. Threshold(s) that is/are crossed or reached:

 

8%

 

8. Notified details:

A: Voting rights attached to shares

 

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

Ordinary 1p Shares

 

18,688,098

18,688,098

1,868,809

8.22%

GB00B13TCY87

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/ converted.

 

% of voting rights

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financial instrument

Exercise price

Expiration date

Exercise/ Conversion period

Number of voting rights instrument refers to

% of voting rights

 

Nominal

Delta

 

 

Total (A+B+C)

 

Number of voting rights

Percentage of voting rights

1,868,809

8.22%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

 

Bank of New York - 1,868,809

 

Proxy Voting:

 

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease to hold:

 

12. Date on which proxy holder will cease to hold voting rights:

 

 

13. Additional information:

 

14. Contact name:

 

Samantha Edwards

15. Contact telephone number:

 

01491 413681

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLSEWFEEFSSEFW
Date   Source Headline
9th Oct 20185:02 pmRNSForm 8.3 - Realm Therapeutics PLC
9th Oct 201810:13 amRNSForm 8.3 - Realm Therapeutics plc
5th Oct 20186:08 pmBUSForm 8.3 - Realm Therapeutics PLC
5th Oct 20182:00 pmRNSFORM 8.3 - Realm Therapeutics Plc
4th Oct 20188:57 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics plc
2nd Oct 201810:43 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics PLC
1st Oct 20187:00 amRNSProvides Update on Timing of Formal Sale Process
24th Sep 20189:59 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
21st Sep 201811:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Sep 20185:06 pmRNSForm 8.3 - Realm Therapeutics plc
20th Sep 20185:06 pmRNSForm 8.3 - Realm Therapeutics plc
20th Sep 20183:16 pmRNSHolding(s) in Company
20th Sep 201811:53 amRNSForm 8.3 - REALM THERAPEUTICS PLC
20th Sep 201811:18 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
19th Sep 20184:31 pmRNSForm 8 (OPD) - Realm Therapeutics plc
19th Sep 201811:11 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
18th Sep 201812:02 pmRNSForm 8.3 - Realm Therapeutics PLC
18th Sep 201811:19 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
17th Sep 20187:00 amRNSCorporate Update and Hiring of Advisor
20th Aug 201811:00 amRNSPrice Monitoring Extension
20th Aug 20187:00 amRNSBlock listing Interim Review
15th Aug 20184:35 pmRNSPrice Monitoring Extension
14th Aug 20187:10 amRNSHalf-year Report
8th Aug 20187:00 amRNSPresents at Wedbush PacGrow Healthcare Conference
7th Aug 20187:00 amRNSNotice of Results
16th Jul 20185:33 pmRNSHolding(s) in Company
10th Jul 20187:00 amRNSPre-Clinical Study in Atopic Dermatitis
4th Jul 20187:00 amRNSInstructions for Exchanging Ordinary Shares
4th Jul 20187:00 amRNSSEC registration effective NASDAQ listing approved
14th Jun 201810:54 amRNSResult of AGM
31st May 20187:00 amRNSRealm to Present at June Investor Conferences
24th May 20187:00 amRNSEnrollment complete for Phase 2 study of PR022
23rd May 20187:00 amRNSFiling with US SEC to Facilitate Nasdaq Listing
21st May 20187:00 amRNSData Presentation at IID 2018
2nd May 201812:39 pmRNSAnnual Financial Report Available
2nd May 20187:00 amRNSFinal Results
2nd May 20187:00 amRNSRealm Files Registration for Nasdaq Listing of ADS
26th Apr 20182:32 pmRNSNotice of Results
12th Mar 20184:40 pmRNSSecond Price Monitoring Extn
12th Mar 20184:35 pmRNSPrice Monitoring Extension
12th Mar 20187:00 amRNSClinical Update including PR013 Phase II results
8th Mar 20187:00 amRNSPresenting at Cowen Healthcare Conference
27th Feb 20187:00 amRNSPatent portfolio strengthened with USPTO allowance
20th Feb 201812:00 pmRNSPresentation at RBC Healthcare Conference
16th Feb 20187:00 amRNSBlock listing Interim Review
15th Feb 20187:00 amRNSClinical and Business Update
2nd Jan 20187:00 amRNSPresents at 5th Annual Dermatology Summit
15th Dec 20177:00 amRNSDirector/PDMR Shareholding
12th Dec 20177:00 amRNSFirst Patient Dosed in Phase 2 Study of PR013
5th Dec 20177:00 amRNSFirst Patient Dosed in Phase 2 Study of PR022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.